Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
Although cannabis’ major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/6/1303 |
| _version_ | 1797540411637497856 |
|---|---|
| author | Francesco Bartoli Ilaria Riboldi Bianca Bachi Angela Calabrese Federico Moretti Cristina Crocamo Giuseppe Carrà |
| author_facet | Francesco Bartoli Ilaria Riboldi Bianca Bachi Angela Calabrese Federico Moretti Cristina Crocamo Giuseppe Carrà |
| author_sort | Francesco Bartoli |
| collection | DOAJ |
| description | Although cannabis’ major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has investigated CBD for the treatment of co-occurring psychotic and cannabis use disorders so far, even though its utility seems grounded in a plausible biological basis. The aim of this work is thus to provide an overview of available clinical studies evaluating the efficacy of CBD for psychotic symptoms induced by THC, schizophrenia, and cannabis use disorders. After searching for relevant studies in PubMed, Cochrane Library, and ClinicalTrials.gov, we included 10 clinical studies. Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia. In addition, preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Evidence from ongoing clinical studies will provide insight into the possible role of CBD for treating psychotic and cannabis use disorders. |
| first_indexed | 2024-03-10T13:00:44Z |
| format | Article |
| id | doaj.art-313dce0f794c44069e898c39ede1ef28 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T13:00:44Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-313dce0f794c44069e898c39ede1ef282023-11-21T11:31:27ZengMDPI AGJournal of Clinical Medicine2077-03832021-03-01106130310.3390/jcm10061303Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative ReviewFrancesco Bartoli0Ilaria Riboldi1Bianca Bachi2Angela Calabrese3Federico Moretti4Cristina Crocamo5Giuseppe Carrà6Department of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, ItalyDepartment of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, ItalyDepartment of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, ItalyDepartment of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, ItalyDepartment of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, ItalyDepartment of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, ItalyDepartment of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, ItalyAlthough cannabis’ major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has investigated CBD for the treatment of co-occurring psychotic and cannabis use disorders so far, even though its utility seems grounded in a plausible biological basis. The aim of this work is thus to provide an overview of available clinical studies evaluating the efficacy of CBD for psychotic symptoms induced by THC, schizophrenia, and cannabis use disorders. After searching for relevant studies in PubMed, Cochrane Library, and ClinicalTrials.gov, we included 10 clinical studies. Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia. In addition, preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Evidence from ongoing clinical studies will provide insight into the possible role of CBD for treating psychotic and cannabis use disorders.https://www.mdpi.com/2077-0383/10/6/1303CannabidiolΔ-9-tetrahydrocannabinolschizophreniapsychotic disorderscannabis use disorderdual diagnosis |
| spellingShingle | Francesco Bartoli Ilaria Riboldi Bianca Bachi Angela Calabrese Federico Moretti Cristina Crocamo Giuseppe Carrà Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review Journal of Clinical Medicine Cannabidiol Δ-9-tetrahydrocannabinol schizophrenia psychotic disorders cannabis use disorder dual diagnosis |
| title | Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
| title_full | Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
| title_fullStr | Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
| title_full_unstemmed | Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
| title_short | Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
| title_sort | efficacy of cannabidiol for δ 9 tetrahydrocannabinol induced psychotic symptoms schizophrenia and cannabis use disorders a narrative review |
| topic | Cannabidiol Δ-9-tetrahydrocannabinol schizophrenia psychotic disorders cannabis use disorder dual diagnosis |
| url | https://www.mdpi.com/2077-0383/10/6/1303 |
| work_keys_str_mv | AT francescobartoli efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT ilariariboldi efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT biancabachi efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT angelacalabrese efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT federicomoretti efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT cristinacrocamo efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT giuseppecarra efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview |